Mirum Pharmaceuticals (MIRM) Set to Post Earnings on Tuesday

Key Points

• Mirum Pharmaceuticals is scheduled to report Q3 2026 results after the market closes on Tuesday, November 3. Analysts expect a loss of $0.4869 per share on revenue of $178.07 million.
• In the previous quarter, Mirum reported a larger-than-expected loss of $1.06 per share but exceeded revenue expectations with $176.24 million, up 37.9% year over year.
• Wall Street remains broadly bullish: the stock has a “Moderate Buy” consensus rating and a $148.19 average price target, although insiders sold nearly $9.8 million of shares over the past three months.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.4869) per share and revenue of $178.07 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to analysts' expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%. The firm's revenue for the quarter was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. On average, analysts expect Mirum Pharmaceuticals to post ($1.32) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Mirum Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ MIRM opened at $83.27 on Tuesday. The company has a 50-day simple moving average of $91.43 and a 200-day simple moving average of $98.41. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a 12 month low of $63.23 and a 12 month high of $130.00.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the sale, the chief executive officer owned 194,440 shares of the company's stock, valued at $19,187,339.20. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total value of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares of the company's stock, valued at $61,600. This trade represents a 51.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 98,499 shares of company stock worth $9,797,834. 8.32% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Stifel Nicolaus lifted their price objective on Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a "buy" rating in a research note on Wednesday, October 14th. TD Cowen upped their price target on Mirum Pharmaceuticals from $140.00 to $145.00 and gave the stock a "buy" rating in a report on Wednesday, October 21st. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. Morgan Stanley raised their target price on Mirum Pharmaceuticals from $137.00 to $152.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Finally, Royal Bank Of Canada raised their price objective on Mirum Pharmaceuticals from $135.00 to $155.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $148.19.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company's medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum's lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.